CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
低收入和中等收入国家是否应采用自动化去中心化 CAR-T 细胞生产模式？真实世界视角
英文原题：Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective.
查看英文原题
Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自体CAR-T（CAR-T）细胞疗法已证明其作为癌症，尤其是血液系统恶性肿瘤的有效治疗方式，并且也正在成为实体器官癌症的潜在候选疗法。然而，由于制造基因修饰的自体产品相关的复杂性和成本，治疗的可及性受到限制。在发达国家已成为主导模式的CAR-T 集中式制造模式，似乎不太适合发展中经济体的需求和现实。在此背景下，我们从发展中国家的视角探讨这两种模式的相对优势和劣势。
展开英文摘要原文
Autologous chimeric antigen receptor-T (CAR-T) cell therapy has proven itself as an effective therapeutic modality for cancers, especially hematological malignancies and is emerging as a potential candidate for solid organ cancers as well.
However, the accessibility to treatment has been limited due to complexities and costs associated with manufacturing a genetically modified autologous product. The centralized model of CAR-T manufacturing which has emerged as the dominant model in developed nations does not seem well-suited to the needs and realities of the developing economies. In this context, we explore the relative advantages and disadvantages of the two models from a developing nation's perspective.
论文信息
- 作者
- Ramakrishnan S、Kumar J、Datta SS、Radhakrishnan V、Nair R、Chandy M
- 单位
- Department of Clinical Haematology and Cellular Therapies, Tata Medical Center, Kolkata, India.India
- 期刊
- Frontiers in oncology2022
- 原文标识
- PubMed 36531042 · DOI 10.3389/fonc.2022.1062296
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →